Accessibility Menu
Viridian Therapeutics Stock Quote

Viridian Therapeutics (NASDAQ: VRDN)

$22.15
(-7.8%)
-1.87
Price as of October 22, 2025, 9:54 a.m. ET

KEY DATA POINTS

Current Price
$23.44
Daily Change
(-7.8%) $1.87
Day's Range
$23.11 - $23.94
Previous Close
$24.02
Open
$23.66
Beta
0.76
Volume
952,298
Average Volume
823,633
Market Cap
2B
Market Cap / Employee
$24.02M
52wk Range
$9.9 - $27.2
Revenue
-
Gross Margin
-2.55%
Dividend Yield
N/A
EPS
-$4.27
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Viridian Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VRDN-2.24%+230.1%+26.98%-87%
S&P+15.06%+95.03%+14.29%+188%

Viridian Therapeutics Company Info

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.08M4.2%
Gross Profit-$0.24M49.4%
Gross Margin-317.33%335.4%
Market Cap$1.14B37.4%
Market Cap / Employee$7.98M0.0%
Employees14349.0%
Net Income-$100.74M-55.0%
EBITDA-$106.45M-48.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$117.32M9.0%
Accounts Receivable$0.00M-100.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$14.05M-26.4%
Short Term Debt$8.99M158.9%

Ratios

Q2 2025YOY Change
Return On Assets-56.33%-7.7%
Return On Invested Capital-49.63%35.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$75.42M-63.4%
Operating Free Cash Flow-$75.37M-63.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book3.152.932.262.7426.58%
Price to Sales5003.505081.453630.863739.9229.65%
Price to Tangible Book Value3.152.932.262.7426.58%
Enterprise Value to EBITDA-11.67-11.78-7.18-7.4110.28%
Return on Equity-51.9%-45.8%-49.4%-63.0%16.73%
Total Debt$23.27M$23.10M$23.11M$23.04M2.14%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.